

Minutes of the Institute Biosafety Committee Meeting

June 10, 2026

Convened at: 1:08 pm and Adjourned at 1:27 pm

Present: Drs. Gelman (Chair), Ding, Fang, Gerber, McGray, Thanavala, Mr. Hartley, Ms. Holtz, Ms Keough and Mr. Flagler.

Absent: Dr. Ionov, Mr. Atwal, Mr Caruana and Ms Bennett

ORSP Staff: Ms Pusateri, Ms Herter

Guests: None

Meeting Place: Virtual meeting/Teams.

Minutes of May 13, 2026 were approved.

Vote: Unanimous.

Adverse Event/Accident/Incident Report

May Employee Health Service report; no incidents.

ORSP - No reports.

Old Business

1. Safety Story; this months story highlighted attention to detail when disinfecting equipment. Laboratory inspections; February, March and May are pending:
Laboratories were visited February 5th with Dr. Thanavala joining the team.
 - a. Evans BSL 2 lab: OES to follow up (see checklist).
 - b. Repasky BSL2 lab: OES to follow up (see checklist).
 - c. Webster BSL2+ lab: OES to follow up (see checklist).Laboratories were visited March 5th with Dr. Ionov joining the team.
 - a. Barbi BSL 2+ lab: OES to follow up (see checklist).
 - b. Goodrich BSL2 lab: OES to follow up (see checklist).
 - c. Wilde BSL2+ lab: OES to follow up (see checklist).Laboratories were visited May 7th with Dr. McGray joining the team.
 - a. Abel BSL 2+ lab: OES to follow up (see checklist).
 - b. Shafirstein BSL2 lab: OES to follow up (see checklist).
2. The administrative staff reported that the Annual NIH Biosafety report has been submitted.
Update 6/10: The annual report has been accepted.

New Business:

1. Lab educational visits:
The next inspection dates will be Thursday June 11th with Dr. Ionov (and Ms Bennett) joining the team and Thursday July 2nd with Dr. McGray joining the team.

Protocol review:

5 Biosafety applications were reviewed.

2 Protocols referenced Virus

Application for 1335M/Lab Based: Approved.

Reviewed by Dr. Fang

The amendment application for full committee review 25-12-1715 entitled: "Dr. Takabe Lab based Biosafety Application." PI: Takabe, Kazuaki was approved.

The purpose of this protocol is to study novel CAR-T therapies for breast cancer using mouse tumor models.

Biosafety agents include: Lenti and retro virus and compounds.

Application for 1426M/Lab Based: Approved pending.

Reviewed by Dr. McGray

The 1426M/lab based application, 26-04-1735 entitled: "Characterizing Molecular Drivers of and Therapeutic Approaches for Pancreatic Cancer." PI: Abel, Ethan was approved pending designated member review of a revised application.

The purpose of this protocol is to identify and testing potential genetic drivers of pancreatic cancer in cell and mouse tumor models.

Biosafety agents include: lentivirus, retrovirus, adenovirus, and compounds.

Exempt from full committee review: none

Amendments:

Application for 1346M/Lab: Approved.

Reviewed by Dr. Gelman

The amendment to 1346M/Lab based 25-07-1682 entitled: "McGray Lab Biosafety" PI: McGray, AJ Robert was approved on 5/18/2026.

Biosafety agents used include: Modified human cell line.

Application for 1642M/Lab: Approved.

Reviewed by Dr. Gelman

The amendment to 1642M/Lab based 25-02-1656 entitled: "Deciphering the Interplay Between Metabolism and Tumor Initiation, Growth and Progression" PI: Wilde, Blake was approved 5/29/2026.

Biosafety agents used include: new AAV vectors and CRISPR modified murine cell line.

Application for Lab/1625M: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based/1624M 24-09-1627 entitled: "Combination Small Molecule Inhibitor and T Cell Immunotherapy Approaches in ALL" PI: Niswander, Lisa was approved 6/4/2026.

Biosafety agents used include: new compound and CAR T cells.

See attached for complete list.

Respectfully Submitted,



Irwin Gelman, PhD
Institute Biosafety Committee Chair
Director of Research Integration; Professor of
Oncology